Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

xlomafota13 shared this article with you from Inoreader Successful encorafenib desensitization in a patient with recurrent metastatic melanoma Via Melanoma Research - Published Ahead-of-Print Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited. Received 21 February 2021 Accepted 18 May 2021 Correspondence to Gerald W. Volcheck, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA, Tel: +1 507 284 3165; fax: +1 507 284 0902; e-mail: volcheck.gerald@mayo.edu Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.